publicaciones seleccionadas
-
artículo académico
- Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Tria. Journal of the National Cancer Institute. 112:1030-1037. 2020
- Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. Journal of Infectious Diseases. 2020
- Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials. Journal of the National Cancer Institute. 112:818-828. 2020
- Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. Journal of the National Cancer Institute. 112:1038-1046. 2020
- An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. Journal of the National Cancer Institute. 111:923-932. 2019
- Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes . The Journal of Infectious Diseases. 220:1609-1619. 2019
- Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial. Journal of the National Cancer Institute. 110:205-212. 2018
- Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies. Vaccine. 36:4774-4782. 2018
- T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study. PLoS ONE. 13. 2018
- Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18‐Year follow‐up of the Guanacaste cohort. International Journal of Cancer. 140:1926-1934. 2017
- Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Journal of Proteomics. 150:201-215. 2017
- Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. American Journal of Obstetrics and Gynecology. 215:212.e1-212.e15. 2016
- Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections. Journal of Infectious Diseases. 213:939-947. 2015
- Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. BMJ Journal. 351. 2015
- Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. Journal of the National Cancer Institute. 108. 2015
- Performance of Self-Collected Cervical Samples in Screening for Future Precancer Using Human Papillomavirus DNA Testing. Journal of the National Cancer Institute. 107. 2015
- Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. Vaccine. 33:2141-2151. 2015
- Alterations of T-cell surface markers in older women with persistent human papillomavirus infection. International Journal of Cancer. 128:597-607. 2011
- Behavioral/Lifestyle and Immunologic Factors Associated with HPV Infection among Women Older Than 45 Years. Cancer Epidemiology Biomarkers & Prevention. 19:3044-3054. 2010
- Elevated Systemic Levels of Inflammatory Cytokines in Older Women with Persistent Cervical Human Papillomavirus Infection. Cancer Epidemiology Biomarkers & Prevention. 19:1954-1959. 2010
- Persistent Human Papillomavirus Infection Is Associated with a Generalized Decrease in Immune Responsiveness in Older Women. Cancer Research . 66:11070-11076. 2006